In a nutshell This study investigated the effectiveness and safety of combination regimens of brentuximab vedotin (BV; Adcetris), ipilimumab (Yervoy), and nivolumab (Opdivo) in patients with relapsed/refractory Hodgkin lymphoma (HL). The data showed that the treatment combinations had promising effectiveness and manageable side effects. Some background...
Read More
In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...
Read More
In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients. Some background B-NHL is a type of...
Read More
In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...
Read More
In a nutshell This study aimed to investigate the outcomes for patients with multiple myeloma (MM) who were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (Decadron) after relapsing following lenalidomide (Revlimid) treatment. This study concluded that this treatment combination was effective in...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including lung cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These tumors...
Read More
In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including melanoma. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated....
Read More
In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients. Some...
Read More
In a nutshell This study aimed to investigate the long-term outcomes of dasatinib treatment for patients with chronic myeloid leukemia who were resistant or intolerant to imatinib in daily clinical practice. This study concluded that dasatinib is safe and effective in these patients. Some background...
Read More
In a nutshell This study aimed to investigate if allogeneic stem cell transplantation (allo-SCT) was a safe and effective option for the treatment of patients with chronic lymphocytic leukemia (CLL) after treatment with novel agents (NA). This study concluded that this treatment option was safe and effective for patients with...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of C-CAG including cladribine (Leustatin), granulocyte colony-stimulating factor (G-CSF, Neupogen), cytarabine (Cytosar-U), and aclarubicin (Aclacinon) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML). This study...
Read More
